Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.35 |
| ▸ | ABAT | P80404 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18530063 | 0.98 | ALDH1A1 (0.50) | ALDH1A1PARP10PARP3ADRB2ADRB1 | |
| SCHEMBL300884 | 0.88 | CA12 (0.42) | ALDH1A1HPGDCA12CA1CA9 | |
| SCHEMBL723217 | 0.85 | ALDH1A1 (0.35) | ALDH1A1HPGDCA12CA1CA9 | |
| SCHEMBL9554693 | 0.84 | PTPN1 (0.35) | ALDH1A1HPGDCA12CA1CA9 | |
| SCHEMBL7868373 | 0.83 | ALDH1A1 (0.41) | ALDH1A1HPGDCA12CA1CA9 | |
| SCHEMBL22046417 | 0.83 | F3 (0.44) | ALDH1A1HPGDCA12CA1CA9 | |
| SCHEMBL13455758 | 0.82 | SMN1; SMN2 (0.44) | ALDH1A1HPGDCA12CA1CA9 | |
| SCHEMBL14727909 | 0.82 | DRD1 (0.43) | CA12CA1CA9MAPT | |
| SCHEMBL9626036 | 0.81 | GRIN2D (0.38) | ALDH1A1CA1KMT2AMAPTKDM4E | |
| SCHEMBL5648489 | 0.81 | CA12 (0.47) | ALDH1A1HPGDCA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50754-E1 | Compositions and method for multiplex biomarker profiling | THE UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2026-01-20 | — | — | US | claimed |
| US-RE50555-E1 | Compositions and method for multiplex biomarker profiling | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2025-08-26 | — | — | US | claimed |
| US-RE49304-E1 | Compositions and method for multiplex biomarker profiling | UNIVERSITY OF WASHINGTON (US) | 2022-11-22 | — | — | US | claimed |
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | AMUNIX PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | claimed |
| EP-2971064-B1 | PROXIMITY ASSAY FOR IN SITU DETECTION OF TARGETS | VENTANA MED SYST INC (US) | 2019-10-16 | — | — | EP | claimed |
| US-20180263927-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC (US) | 2018-09-20 | — | — | US | claimed |
| EP-2494075-B1 | TEMPLATED NANOCONJUGATES | UNIV NORTHWESTERN (US) | 2018-04-04 | — | — | EP | claimed |
| EP-2714752-B1 | METHODS FOR COUPLING TARGETING PEPTIDES ONTO RECOMBINANT LYSOSOMAL ENZYMES FOR IMPROVED TREATMENTS OF LYSOSOMAL STORAGE DISEASES | AMICUS THERAPEUTICS INC (US) | 2017-11-22 | — | — | EP | claimed |
| WO-2017189448-A1 | BIVALENT IMMUNOGENIC CONJUGATE FOR MALARIA AND TYPHOID | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-11-02 | — | — | WO | claimed |
| US-9663814-B2 | Proximity assay for in situ detection of targets | VENTANA MEDICAL SYSTEMS, INC. (US) | 2017-05-30 | — | — | US | claimed |
| EP-1933878-A2 | CONJUGATES OF HYDROXYALKYL STARCH AND AN ACTIVE SUBSTANCE, PREPARED BY CHEMICAL LIGATION VIA THIAZOLIDINE | Fresenius Kabi Deutschland GmbH (DE) | 2008-06-25 | — | — | EP | claimed |
| US-20070254311-A1 | Covalent modification and conjugation of luciferase | CARDIOGENICS INC. (CA) | 2007-11-01 | — | — | US | claimed |
| US-20070134197-A1 | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2007-06-14 | — | — | US | claimed |
| WO-2007031266-A2 | CONJUGATES OF HYDROXYALKYL STARCH AND AN ACTIVE SUBSTANCE, PREPARED BY CHEMICAL LIGATION VIA THIAZOLIDINE | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2007-03-22 | — | — | WO | claimed |
| EP-1762250-A1 | Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine | Fresenius Kabi Deutschland GmbH (DE) | 2007-03-14 | — | — | EP | claimed |
| US-20060153839-A1 | Production of bispecific molecules using polyethylene glycol linkers | ELUSYS THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | US | claimed |
| EP-1539811-A4 | PRODUCTION OF BISPECIFIC MOLECULES USING POLYETHYLENE GLYCOL LINKERS | ELUSYS THERAPEUTICS INC (US) | 2006-05-24 | — | — | EP | claimed |
| WO-2005092928-A1 | CONJUGATES OF HYDROXYALKYL STARCH AND A PROTEIN, PREPARED BY REDUCTIVE AMINATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2005-10-06 | — | — | WO | claimed |
| EP-1539811-A2 | PRODUCTION OF BISPECIFIC MOLECULES USING POLYETHYLENE GLYCOL LINKERS | Elusys Therapeutics, Inc. (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004024889-A2 | PRODUCTION OF BISPECIFIC MOLECULES USING POLYETHYLENE GLYCOL LINKERS | ELUSYS THERAPEUTICS, INC. (US) | 2004-03-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | XPA, TXLNA, NGLY1 | ALDH1A1 3685/4885PARP10 701/4885PARP3 2473/4885 |
| US-20060153839-A1 | Production of bispecific molecules using polyethylene glycol linkers | TNFSF11, TNFSF10, CLTA | ALDH1A1 3916/4885PARP10 895/4885PARP3 944/4885 |
| US-20070134197-A1 | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination | DERA, HBG1, HACL2 | ALDH1A1 478/4885PARP10 1401/4885PARP3 1176/4885 |
| US-20180263927-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | ALDH1A1 3966/4885PARP10 1363/4885PARP3 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.